Ac Immune Sa · NASDAQ:ACIU
Ac Immune Sa — AAIC 2022
13 slides from Ac Immune Sa's conference presentation, Aug 2, 2022
Slide 1: Optimized ACI-24, an Abeta vaccine targeting oligomers and pyroglutamate Abeta
Optimized ACI-24, an amyloid beta (Abeta) vaccine that safely drives immunity to oligomers and Pyroglutamate Abeta, key pathological species of Alzheimer’s disease (AD) Emma Fiorini, PhD | AAIC 2022 | 2 August
Slide 2: Disclaimer
Disclaimer This presentation contains statements that constitute “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Forward-looking statements are statements other than historical fact and may include s
Slide 3: Different modalities for mono- or combination-therapeutic options
Different modalities for mono- or combination-therapeutic options In Alzheimer’s and Parkinson’s diseases, pathology exists outside and inside the neuron Extracellular pathology with local inflammation Intracellular aggregation and misfolding and transport from cell to cell causing cells to die Mono
Slide 4: The rationale for anti Abeta vaccination in AD and AD in Down syndrome
The rationale for anti Abeta vaccination in Alzheimer’s disease (AD) and AD in Down syndrome (DS) Unique possibility for treatment and prevention of AD1 in a more homogeneous genetic population Factors supporting a vaccine approach in DS Alzheimer’s disease in Autosomal dominant Amyloid-beta precu
Slide 5: Optimized ACI-24: a vaccine targeting Abeta 1-15
Optimized ACI-24: a vaccine targeting Abeta 1-15 Includes bystander T-cell help ACI-24 Optimized ACI-24 Abeta1-15 Abeta1-15 (B-cell peptide) (B-cell peptide) Liposomal anchor Liposomal anchor Adjuvant (Palmitic chains) Adjuvant (Palmitic chains) T-cell Peptide (non-target) Liposomal bilayer Liposoma
Slide 6: Increased and prolonged immunogenicity with optimized ACI-24
Increased and prolonged immunogenicity with optimized ACI-24 Anti-Abeta1-42 IgG titers in mice and non-human primates (NHPs) Ref.: AC Immune; Global Down Syndrome Forum 2021 Optimized ACI-24 in mice Optimized ACI-24 in NHPs antibody concentration (AU/mL) antibody concentration (AU/mL) 10 6 10 6 Opti
Slide 7: Targets multiple Abeta species
Targets multiple Abeta species Response against Abeta1-42 and pyroGlu Abeta1 in NHPs Optimized ACI-24 in NHPs Abeta pyroGlu Abeta ✱✱✱✱ Ref.: Jawhar S et al,; J of Biol Chem 2011 ✱✱✱✱ 10 6 ✱✱✱✱ ✱✱✱✱ IgG antibody titer 10 5 ✱✱✱✱ ✱✱✱ (AU/mL)2 10 4 10 3 10 2 10 1 3 4 3 4 Predose 36 92 Predose 36 92 Days
Slide 8: Unique antibody profile versus other Abeta vaccines
Unique antibody profile versus other Abeta vaccines Superior pyroGlu Abeta recognition and epitope coverage in NHPs Optimized ACI-24 generates high antibody Optimized ACI-24-induced antibodies recognize a broad range titers against pyroGlu Abeta of N-terminal Abeta epitopes Ref.: M. Vukicevic, et al
Slide 9: Targets oligomers, induces antibody maturation and binds Abeta
Targets oligomers, induces antibody maturation and binds Abeta Further characterization post immunization of NHPs IgGs titers against oligomers Avidity index Abeta 1-40 and 1-42 protein level ✱✱✱ ✱ ✱ 10 6 ✱ 1.0 900 60 oligomers IgG (AU/mL) ✱ ✱ Abeta Avidity index Abeta1-40 levels in Abeta1-42 levels
Slide 10: Produces antibodies that bind Abeta in human plaques
Produces antibodies that bind Abeta in human plaques Using AD patient-derived brain tissue sections Positive control NHP serum, NHP serum, mAb 4G8 Day 641 before immunization Ref.: AC Immune; Global Down Syndrome Forum 2021 Dapi Dapi Dapi Abeta Abeta Abeta ■ Antibodies generated in NHPs post-vaccina
Slide 11: Summary
Summary Optimized ACI-24, in addition to the Abeta1-15 peptide presented on the surface of the liposome to cross-link the BCR, has a non-Abeta T-cell peptide to enhance and maintain anti-Abeta-specific antibody responses Optimized ACI-24 induces strong and sustained IgG titers against key pathol
Slide 12: Acknowledgements
Acknowledgements Andrea Pfeifer Sophie Bravo-Veyrat Marie Kosco-Vilbois Valérie Giriens Marija Vukicevic Catherine Morici Rakel Carpintero Aurélie Guillaume-Gentil Marcela Rincon Marie-Gabrielle Beuzelin Pili Lopez-Deber Anthony Gesbert Nicolas Piot Sébastien Rivot Maxime Ayer Nathalie Chuard Inmacu
Slide 13: AC Immune
AC Immune We continue to shape the future of neurodegeneration by discovering and developing breakthrough therapies through pioneering science and precision medicine Web: https://www.acimmune.com/ Social media: www.linkedin.com/company/ac-immune Presenter: emma.fiorini@acimmune.com Business developm